partnering

News

Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer.

News

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

News

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

News

Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.

News

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

News

A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.